2. Academic Validation
  3. High-throughput combinatorial screening of antiplatelet drugs for personalized medicine

High-throughput combinatorial screening of antiplatelet drugs for personalized medicine

  • Microsyst Nanoeng. 2026 Jan 1;12(1):7. doi: 10.1038/s41378-025-01126-8.
Chenguang Wang # 1 2,  Wenjie Zhu # 3,  Jiawei Zhu 3,  Tian Gao 3,  Zheyi Jiang 1,  Tiantian Zhang 1,  Long Chen 3,  Junfeng Zhang 4,  Yifan Liu 5,  Alex Chia Yu Chang 6 7
Affiliations

Affiliations

  • 1 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, China.
  • 2 Shanghai Institute of Precision Medicine, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200125, Shanghai, China.
  • 3 School of Physical Science and Technology, ShanghaiTech University, 201210, Shanghai, China.
  • 4 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, China. [email protected].
  • 5 School of Physical Science and Technology, ShanghaiTech University, 201210, Shanghai, China. [email protected].
  • 6 Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, China. [email protected].
  • 7 Shanghai Institute of Precision Medicine, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200125, Shanghai, China. [email protected].
  • # Contributed equally.
PMID: 41476049 DOI: 10.1038/s41378-025-01126-8
Abstract

Cardiovascular Disease (CVD) remains the leading cause of death worldwide. Platelet activation plays a critical role in arterial thrombotic events such as myocardial infarction. Although antiplatelet drugs are standard therapies, they are associated with risks including bleeding, gastrointestinal adverse effects, and drug resistance. Furthermore, substantial inter-individual variability in patient responses underscores the need for personalized antiplatelet regimens. These factors emphasize the importance of screening for optimal antiplatelet drugs and drug combinations tailored to individual patients. However, traditional platelet detection assays are reagent-hungry and low-throughput, making them unsuitable for high-throughput screening of antiplatelet agents. Here, we present the C-chip, a high-throughput platform for on-chip parallel screening of antiplatelet drug combinations. The C-chip miniaturizes individual screening reactions into picoliter-volume, color-coded droplets, enabling the generation of thousands of screening data points in a single experiment. We demonstrate that the C-chip can effectively identify the optimal combinations of three clinically relevant antiplatelet drugs: Aspirin, Tirofiban, and Ticagrelor. We further applied this platform to identify optimal drug combinations for five healthy volunteers, revealing marked inter-individual variability in antiplatelet drug responses.

Figures
Products